Product logins

Find logins to all Clarivate products below.


Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | 2023

CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Janssen’s Carvykti, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and patients with R/R multiple myeloma. Priced at more than $400,000 per infusion, these therapies also come with unique administrative and budgetary challenges for managed care organizations (MCOs) and providers. As the market for these novel therapies grows, we explore how MCO pharmacy directors and medical directors (PDs/MDs) approach reimbursement of these expensive therapies for NHL and multiple myeloma and how coverage decisions in their largest commercial and Medicare Advantage plans impact prescribing among surveyed hematologist-oncologists.

Questions Answered

  • What factors drive physicians’ choice of a CAR T-cell therapy, both in second line and later lines of therapy?
  • How are CAR T-cell therapies covered in commercial and Medicare plans, and what kind of contracts and payment schemes do MCOs commonly use to address the therapies’ high cost?
  • What prior authorization requirements and other utilization management controls do payers apply to CAR T-cell therapies, and how do these restrictions affect hematologist-oncologists’ prescribing?
  • How will access to CAR T-cell therapies be affected by off-the-shelf bispecific antibodies, such as Roche’s Lunsumio for R/R NHL and Janssen Biotech’s Tecvayli for R/R multiple myeloma? Will MCOs encourage patients to use these therapies before a CAR T-cell therapy?

Content Highlights

Geography: United States.

Primary research: Survey of 100 U.S. hematologist-oncologists; survey of 40 U.S. managed care organization (MCO) pharmacy and medical directors (PDs / MDs).

Key drugs covered: Breyanzi, Kymriah, Tecartus. Yescarta, Abecma, Carvykti

Key analysis provided:

  • Reimbursement and contracting
  • Access and prescribing
  • Opportunities and challenges for emerging therapies

Product Description

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…